Last updated 5 days ago
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
360 patients around the world
Available in Puerto Rico, Spain, Colombia, United States, Mexico, Argentina, Brazil
Bristol-Myers Squibb
3Research sites
360Patients around the world
This study is for people with
Myelodysplastic Syndromes
Requirements for the patient
From 18 Years
All Gender
Medical requirements
StudyELEMENT-MDS
SponsorBristol-Myers Squibb
Conditions
Myelodysplastic Syndromes
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05949684
